CNBC
28 May 2026, 10:45 UTC · 2h ago
CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans
Source · https://www.cnbc.com/2026/05/28/cvs-covers-zepbound-adds-eli-lilly-foundayo.html
Read source
Search tags
CNBC
28 May 2026, 10:45 UTC · 2h ago
Source · https://www.cnbc.com/2026/05/28/cvs-covers-zepbound-adds-eli-lilly-foundayo.html
Read sourceSearch tags
Story key points
3 claims · impact-rated
CVS Health will restore coverage of Eli Lilly's Zepbound and add its new obesity pill, Foundayo, to standard drug plans. — This removes a significant access barrier for Eli Lilly, expanding its addressable market to millions of additional patients.
+0.60CVS Caremark's standard commercial formulary, covering 25 million to 30 million Americans, will now list both Eli Lilly and Novo Nordisk GLP-1s as co-preferred options. — This eliminates Novo Nordisk's previous preferred-status advantage on CVS plans, leveling the competitive playing field.
+0.40CVS expects the new competitive arrangement and pricing negotiations to drive 10% to 15% additional savings across the weight management category. — Lower drug costs are a positive for the PBM's margins and plan sponsors, though it suggests downward pressure on drug pricing.
+0.20Ticker attribution
Model heads
CVS is restoring coverage for Zepbound and adding its new obesity pill, expanding patient access and competitiveness.
The company expects the new formulary arrangements to drive 10% to 15% additional savings in the weight management category.
The company maintains preferred status for Wegovy, though it now faces increased competition from Eli Lilly on CVS plans.
[mutual] Eli Lilly and Novo Nordisk compete for dominance in the blockbuster weight loss drug market.
[a_to_b] Eli Lilly supplies Zepbound and Foundayo to CVS's drug plans.
[a_to_b] Novo Nordisk supplies Wegovy to CVS's drug plans.
[mutual] Eli Lilly partnered with CVS on pricing negotiations to make weight loss drugs more affordable.
[mutual] Novo Nordisk partnered with CVS on pricing negotiations to make weight loss drugs more affordable.
Impact vectors
8 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.